Takeda Pharmaceutical (TAK) Receivables (2017 - 2026)

Takeda Pharmaceutical's Receivables history runs 10 years deep, the most recent figure standing at $6.5 billion for Q1 2026.

• On a quarterly basis, Receivables rose 18.96% year-over-year to $6.5 billion in Q1 2026; TTM through Mar 2026 was $6.5 billion, a 18.96% increase from a year earlier, with the FY2026 full-year figure at $6.7 billion, up 23.74% from the prior year.
• Receivables climbed to $6.5 billion in Q1 2026 per TAK's latest filing, from $4.8 billion in the prior quarter.
• Across five years, Receivables topped out at $6.5 billion in Q1 2026 and bottomed at $347.0 million in Q1 2024.
• The 5-year median for Receivables is $4.8 billion (2023), against an average of $4.4 billion.
• Across the five-year window, Receivables sank 92.29% in 2022 and soared 1465.92% in 2025, its largest moves.
• Year by year, Receivables stood at $5.0 billion in 2022, then declined by 3.22% to $4.8 billion in 2023, then dropped by 3.42% to $4.7 billion in 2024, then grew by 2.26% to $4.8 billion in 2025, then surged by 35.07% to $6.5 billion in 2026.
• Per Business Quant, the three latest TAK Receivables figures stand at $6.5 billion (Q1 2026), $4.8 billion (Q4 2025), and $4.7 billion (Q3 2025).